HC Wainwright downgraded shares of Bionomics (NASDAQ:BNOX – Get Rating) from a buy rating to a neutral rating in a report issued on Monday, The Fly reports.

Separately, Loop Capital initiated coverage on shares of Bionomics in a research report on Tuesday, November 1st. They issued a buy rating and a $23.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $16.67.

Bionomics Price Performance

NASDAQ BNOX opened at $4.71 on Monday. The company has a fifty day simple moving average of $7.51 and a 200 day simple moving average of $7.33. Bionomics has a 12-month low of $4.71 and a 12-month high of $13.76.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

See Also

• Get a free copy of the StockNews.com research report on Bionomics (BNOX)
• Your Decision to Buy Palantir May Simply Be a Matter of Time
• Are Caterpillar and Deere Setting Up to Rally in 2023?
• Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
• Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
• Lucid Motors Faces a Reality That May Cloud a Bullish Perception

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.